TiGenix : presenting at 15th Annual BIO CEO & Investor Conference

Tue Feb 12, 2013 12:01am EST

* Reuters is not responsible for the content in this press release.

For best results when printing this announcement, please click on the link below:

http://pdf.reuters.com/htmlnews/8knews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20130212:nHUGcWcP


february 12, 2013

TiGenix to present at 15th Annual BIO CEO & Investor Conference

Leuven (BELGIUM) - February 12, 2013 - TiGenix (NYSE Euronext: TIG), a leader in the field of cell
therapy, announced today that Eduardo Bravo, CEO, will be presenting at the 15th Annual BIO CEO &
Investor Conference. Hosted by the Biotechnology Industry Organization (BIO), the 15th Annual BIO
CEO & Investor Conference will take place February 11-12 at the Waldorf Astoria in New York City. 

Presentation Details:

Date & time:               Tuesday, February 12, 8:30 - 8:55 AM EST
Presenter:                   Eduardo Bravo, CEO 
Location:                     Conrad Room

Click here for access to live webcast
http://www.veracast.com/webcasts/bio/ceoinvestor2013/57202154.cfm  (registration free, but
required) 
Replay available 1 hour after live event; archived webcast expires May 12, 2013

About TiGenix

TiGenix NV (Euronext Brussels: TIG) is a leading European cell therapy company with a marketed
product for cartilage repair, ChondroCelect(R), and a strong pipeline with clinical stage
allogeneic adult stem cell programs for the treatment of autoimmune and inflammatory diseases.
TiGenix is based out of Leuven (Belgium) and has operations in Madrid (Spain), and Sittard-Geleen
(the Netherlands).  For more information please visit www.tigenix.com. 

About the BIO CEO & Investor Conference

The 15th Annual BIO CEO & Investor Conference is the largest independent investor conference
focused on publicly-traded biotechnology companies.  This year's conference will feature corporate
presentations from more than 150 leading biotechnology and pharmaceutical companies, five Fireside
Chats with industry leaders, three Therapeutic Workshops and five Business Roundtables all drawing
from seasoned industry executives and analysts. New this year, a special track of 25 high-caliber
private companies will be presenting at the event, and plenary sessions will address timely
business issues and industry trends. Attendees can expect many opportunities to schedule
one-on-one meetings as well as numerous networking opportunities. The conference is designed to
foster an informative dialogue between institutional investors and senior biotechnology executives
about emerging and current investment opportunities. Complimentary registration is available to
qualified institutional (buy and sell-side), private equity, and venture investors and can be
accessed here:http://www.bio.org/events/conferences/bio-ceo-investor-registration
http://www.bio.org/events/conferences/bio-ceo-investor-registration .

Forward-looking information 

This document may contain forward-looking statements and estimates with respect to the anticipated
future performance of TiGenix and the market in which it operates. Certain of these statements,
forecasts and estimates can be recognized by the use of words such as, without limitation,
"believes", "anticipates", "expects", "intends", "plans", "seeks", "estimates", "may", "will" and
"continue" and similar expressions. They include all matters that are not historical facts. Such
statements, forecasts and estimates are based on various assumptions and assessments of known and
unknown risks, uncertainties and other factors, which were deemed reasonable when made but may or
may not prove to be correct. Actual events are difficult to predict and may depend upon factors
that are beyond TiGenix' control. Therefore, actual results, the financial condition, performance
or achievements of TiGenix, or industry results, may turn out to be materially different from any
future results, performance or achievements expressed or implied by such statements, forecasts and
estimates. Given these uncertainties, no representations are made as to the accuracy or fairness
of such forward-looking statements, forecasts and estimates. Furthermore, forward-looking
statements, forecasts and estimates only speak as of the date of the publication of this document.
TiGenix disclaims any obligation to update any such forward-looking statement, forecast or
estimates to reflect any change in TiGenix' expectations with regard thereto, or any change in
events, conditions  or circumstances on which any such statement, forecast or estimate is based,
except to the extent required by Belgian law.

For more information:
Eduardo Bravo
Chief Executive Officer
eduardo.bravo@tigenix.com mailto:eduardo.bravo@tigenix.com                         

Claudia D'Augusta
Chief Financial Officer
claudia.daugusta@tigenix.com mailto:claudia.daugusta@tigenix.com 

Hans Herklots
hans.herklots@tigenix.com mailto:hans.herklots@tigenix.com 
+32 16 39 60 97



----------------------------------------------------------------------------------------------------

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: TiGenix via Thomson Reuters ONE


HUG#1677094

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.